Luye Pharma Completes Patient Enrollment for Phase 3 GAD Trial
MT Newswires Live
Aug 18
Luye Pharma Group (HKG:2186) completed patient enrollment for its Phase 3 clinical trial of Ruoxinlin(r) (Toludesvenlafaxine) in China for treating generalized anxiety disorder (GAD), according to a Hong Kong bourse filing Monday.
The multicenter, randomized, double-blind, placebo-controlled trial enrolled 555 participants, with the primary endpoint measuring change in Hamilton Anxiety Scale (HAM-A) scores by week eight.
Luye plans to submit its marketing authorization application by the end of this year.
Shares of the pharmaceutical firm gained over 1% in Monday afternoon trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.